Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Alga supplement could boost sight in rare eye disease

NCT ID NCT07509229

Disease control Sponsor: Sheba Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests whether a natural supplement from Dunaliella alga, rich in 9-cis beta-carotene, can improve vision in adults with retinitis pigmentosa. Forty-one participants will take the supplement or a placebo for 3 months, then switch after a 6-month break. Researchers will measure retinal sensitivity, electrical responses, and blood levels of vitamin A.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
9-cis beta-carotene-rich extract of Dunaliella alga (dietary supplement)
What this could lead to
If it works, this could point toward a natural supplement that slows vision loss or improves light sensitivity in retinitis pigmentosa.
What could go wrong
This is an early Phase 1/2 trial with only 41 people, so results may not apply broadly. The supplement may not improve vision and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 41 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent to participate in the study 2. Men or women aged 18 years or older 3. Electroretinogram (ERG) responses compatible with the diagnosis of retinitis pigmentosa 4. Positive for mutation(s) in retinoid cycle related genes Exclusion Criteria: 1. Currently a smoker 2. Current use of vitamin A/ β-carotene supplements 3. Known mutations in the ABCA4 gene 4. Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery 5. History of malignancy, excepting basal or squamous cell skin carcinoma 6. Women who are pregnant, or breast feeding, or are premenopausal but not using chemical or mechanical contraception 7. Uncontrolled hypertension, defined either as resting diastolic blood pressure \>95 mmHg (taken from the mean of 3 readings) or as resting systolic blood pressure \>180 mmHg 8. History of alcohol abuse or drug abuse or both 9. Intention to engage in vigorous exercise or an aggressive diet regimen 10. Uncontrolled endocrine or metabolic disease 11. Participation in another investigational drug study within 4 weeks prior to enrolment 12. Serious or unstable medical or psychological condition which, in the opinion of the PI, would compromise the subject's safety or successful participation in the study 13. Initiation of hormone replacement therapy or oral contraceptive therapy within 3 months prior to enrolment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retinitis pigmentosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retinitis pigmentosa

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Goldschleger Eye Institute, Sheba Medical Center,

    Tel Litwinsky, 52621, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.